お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ

株式会社グローバルインフォメーション
市場調査レポート
商品コード
966768

キメラ抗原受容体T細胞療法 (CAR-T):疫学考察 (~2030年)

Chimeric Antigen Receptor T-Cell Therapy (CAR-T) - Epidemiology Insight - 2030

出版日: 受注生産 | 発行: DelveInsight Business Research LLP | ページ情報: 英文 100 Pages | 納期: 約10営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=104.84円
キメラ抗原受容体T細胞療法 (CAR-T):疫学考察 (~2030年)
出版日: 受注生産
発行: DelveInsight Business Research LLP
ページ情報: 英文 100 Pages
納期: 約10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、米国、欧州5ヶ国(ドイツ、スペイン、イタリア、フランス、英国)、および日本の7つの主要市場におけるキメラ抗原受容体T細胞療法 (CAR-T) 市場について詳細に説明し、疾患の背景と概要、アンメットニーズ、各国における疫学、治療法などに関する情報を提供しています。

目次

第1章 主な考察

第2章 エグゼクティブサマリー

第3章 キメラ抗原受容体T細胞療法 (CAR-T):疾患の背景と概要

  • イントロダクション
  • 兆候と症状
  • 病態生理学
  • 危険因子
  • 診断

第4章 ペイシェントジャーニー

第5章 疫学と患者人口

  • 疫学の主な調査結果
  • 前提条件と理論的根拠:主要7ヶ国
  • 疫学シナリオ:主要7ヶ国
    • 主要7ヶ国におけるキメラ抗原受容体T細胞療法 (CAR-T)の疫学シナリオ
  • 米国の疫学
    • 米国におけるキメラ抗原受容体T細胞療法 (CAR-T) の疫学シナリオ
  • 欧州5ヶ国の疫学:国別
    • ドイツの疫学
    • フランスの疫学
    • イタリアの疫学
    • スペインの疫学
    • 英国の疫学
  • 日本の疫学
    • 日本におけるキメラ抗原受容体T細胞療法 (CAR-T) の疫学シナリオ

第6章 治療アルゴリズム、現在の治療、および医療行為

  • キメラ抗原受容体T細胞療法 (CAR-T) の治療と管理
  • キメラ抗原受容体T細胞療法 (CAR-T) の治療アルゴリズム

第7章 KOL の見解

第8章 アンメットニーズ

第9章 付録

  • 参考文献
  • レポートの調査手法

第10章 DelveInsightのサービス内容

第11章 免責事項

第12章 DelveInsightについて

図表

List of Tables

  • Table 1: Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Epidemiology in 7MM (2017-2030)
  • Table 2: Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Diagnosed and Treatable Cases in 7MM (2017-2030)
  • Table 3: Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Epidemiology in the United States (2017-2030)
  • Table 4: Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Diagnosed and Treatable Cases in the United States (2017-2030)
  • Table 5: Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Epidemiology in Germany (2017-2030)
  • Table 6: Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Diagnosed and Treatable Cases in Germany (2017-2030)
  • Table 7: Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Epidemiology in France (2017-2030)
  • Table 8: Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Diagnosed and Treatable Cases in France (2017-2030)
  • Table 9: Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Epidemiology in Italy (2017-2030)
  • Table 10: Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Diagnosed and Treatable Cases in Italy (2017-2030)
  • Table 11: Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Epidemiology in Spain (2017-2030)
  • Table 12: Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Diagnosed and Treatable Cases in Spain (2017-2030)
  • Table 13: Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Epidemiology in the United Kingdom (2017-2030)
  • Table 14: Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Diagnosed and Treatable Cases in the United Kingdom (2017-2030)
  • Table 15: Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Epidemiology in Japan (2017-2030)
  • Table 16: Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Diagnosed and Treatable Cases in Japan (2017-2030)

List of Figures

  • Figure 1: Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Epidemiology in 7MM (2017-2030)
  • Figure 2: Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Diagnosed and Treatable Cases in 7MM (2017-2030)
  • Figure 3: Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Epidemiology in the United States (2017-2030)
  • Figure 4: Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Diagnosed and Treatable Cases in the United States (2017-2030)
  • Figure 5: Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Epidemiology in Germany (2017-2030)
  • Figure 6: Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Diagnosed and Treatable Cases in Germany (2017-2030)
  • Figure 7: Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Epidemiology in France (2017-2030)
  • Figure 8: Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Diagnosed and Treatable Cases in France (2017-2030)
  • Figure 9: Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Epidemiology in Italy (2017-2030)
  • Figure 10: Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Diagnosed and Treatable Cases in Italy (2017-2030)
  • Figure 11: Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Epidemiology in Spain (2017-2030)
  • Figure 12: Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Diagnosed and Treatable Cases in Spain (2017-2030)
  • Figure 13: Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Epidemiology in the United Kingdom (2017-2030)
  • Figure 14: Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Diagnosed and Treatable Cases in the United Kingdom (2017-2030)
  • Figure 15: Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Epidemiology in Japan (2017-2030)
  • Figure 16: Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Diagnosed and Treatable Cases in Japan (2017-2030)

The table of contents is not exhaustive; will be provided in the final report

目次
Product Code: DIEI1043

DelveInsight's 'Chimeric Antigen Receptor T-Cell Therapy (CAR-T) - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Chimeric Antigen Receptor T-Cell Therapy (CAR-T) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Understanding

The DelveInsight Chimeric Antigen Receptor T-Cell Therapy (CAR-T) epidemiology report gives a thorough understanding of the Chimeric Antigen Receptor T-Cell Therapy (CAR-T) by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Chimeric Antigen Receptor T-Cell Therapy (CAR-T) in the US, Europe, and Japan. The report covers the detailed information of the Chimeric Antigen Receptor T-Cell Therapy (CAR-T) epidemiology scenario in seven major countries (US, EU5, and Japan).

Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Epidemiology Perspective by DelveInsight

The Chimeric Antigen Receptor T-Cell Therapy (CAR-T) epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Chimeric Antigen Receptor T-Cell Therapy (CAR-T) epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Chimeric Antigen Receptor T-Cell Therapy (CAR-T) epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Detailed Epidemiology Segmentation

The Chimeric Antigen Receptor T-Cell Therapy (CAR-T) epidemiology covered in the report provides historical as well as forecasted Chimeric Antigen Receptor T-Cell Therapy (CAR-T) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.

The DelveInsight Chimeric Antigen Receptor T-Cell Therapy (CAR-T) report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report:

  • The Chimeric Antigen Receptor T-Cell Therapy (CAR-T) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Epidemiology Report and Model provide an overview of the risk factors and global trends of Chimeric Antigen Receptor T-Cell Therapy (CAR-T) in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight about the historical and forecasted patient pool of Chimeric Antigen Receptor T-Cell Therapy (CAR-T) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Chimeric Antigen Receptor T-Cell Therapy (CAR-T)
  • The report provides the segmentation of the Chimeric Antigen Receptor T-Cell Therapy (CAR-T) epidemiology

Report Highlights:

  • 11-Year Forecast of Chimeric Antigen Receptor T-Cell Therapy (CAR-T) epidemiology
  • 7MM Coverage
  • Total Cases of Chimeric Antigen Receptor T-Cell Therapy (CAR-T)
  • Total Cases of Chimeric Antigen Receptor T-Cell Therapy (CAR-T) according to segmentation
  • Diagnosed cases of Chimeric Antigen Receptor T-Cell Therapy (CAR-T)

KOL- Views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Chimeric Antigen Receptor T-Cell Therapy (CAR-T) ?
  • What are the key findings pertaining to the Chimeric Antigen Receptor T-Cell Therapy (CAR-T) epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
  • What would be the total number of patients of Chimeric Antigen Receptor T-Cell Therapy (CAR-T) across the 7MM during the forecast period (2017-2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
  • What is the disease risk, burden and unmet needs of the Chimeric Antigen Receptor T-Cell Therapy (CAR-T) ?
  • What are the currently available treatments of Chimeric Antigen Receptor T-Cell Therapy (CAR-T) ?

Reasons to buy:

  • The Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Epidemiology report will allow the user to -
  • Develop business strategies by understanding the trends shaping and driving the global Chimeric Antigen Receptor T-Cell Therapy (CAR-T) market
  • Quantify patient populations in the global Chimeric Antigen Receptor T-Cell Therapy (CAR-T) market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Chimeric Antigen Receptor T-Cell Therapy (CAR-T) therapeutics in each of the markets covered
  • Understand the magnitude of Chimeric Antigen Receptor T-Cell Therapy (CAR-T) population by its epidemiology
  • The Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Table of Contents

1. Key Insights

2. Executive Summary of Chimeric Antigen Receptor T-Cell Therapy (CAR-T)

3. Chimeric Antigen Receptor T-Cell Therapy (CAR-T) : Disease Background and Overview

  • 3.1. Introduction
  • 3.2. Sign and Symptoms
  • 3.3. Pathophysiology
  • 3.4. Risk Factors
  • 3.5. Diagnosis

4. Patient Journey

5. Epidemiology and Patient Population

  • 5.1. Epidemiology Key Findings
  • 5.2. Assumptions and Rationale: 7MM
  • 5.3. Epidemiology Scenario: 7MM
    • 5.3.1. Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Epidemiology Scenario in the 7MM (2017- 2030)
  • 5.4. United States Epidemiology
    • 5.4.1. Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Epidemiology Scenario in the United States (2017- 2030)
  • 5.5. EU-5 Country-wise Epidemiology
    • 5.5.1. Germany Epidemiology
      • 5.5.1.1. Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Epidemiology Scenario in Germany (2017- 2030)
    • 5.5.2. France Epidemiology
      • 5.5.2.1. Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Epidemiology Scenario in France (2017- 2030)
    • 5.5.3. Italy Epidemiology
      • 5.5.3.1. Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Epidemiology Scenario in Italy (2017- 2030)
    • 5.5.4. Spain Epidemiology
      • 5.5.4.1. Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Epidemiology Scenario in Spain (2017- 2030)
    • 5.5.5. United Kingdom Epidemiology
      • 5.5.5.1. Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Epidemiology Scenario in the United Kingdom (2017-2030)
  • 5.6. Japan Epidemiology
    • 5.6.1. Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Epidemiology Scenario in Japan (2017- 2030)

6. Treatment Algorithm, Current Treatment, and Medical Practices

  • 6.1. Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Treatment and Management
  • 6.2. Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Treatment Algorithm

7. KOL Views

8. Unmet Needs

9. Appendix

  • 9.1. Bibliography
  • 9.2. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

The table of contents is not exhaustive; will be provided in the final report

株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.